GSK’s RSV vaccine candidate contains Agenus’ proprietary QS-21 STIMULON within its AS01 adjuvant, which – in the context of other antigens – has already demonstrated positive immune ...

GSK Licenses Shigella Vaccine altSonflex1-2-3 to Bharat Biotech: Strategic licensing agreement advances late-stage development and expands potential vaccine access in low- and middle-income countries.

Bharat Biotech, GSK team up to develop Shigella vaccine for global health Bharat Biotech will lead Phase 3 clinical trials and large-scale manufacturing, while GSK will support with funding ...

On Friday, February 14, the FDA approved GSK plc’s (NYSE:GSK) Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25. The vaccine targets five major ...

As part of a multi-year collaboration, GSK and India’s Bharat Biotech are redoubling their efforts to bring the world’s first malaria vaccine to more countries in need at affordable prices.

GSK and Bharat Biotech have pledged to reduce the price of the world’s first malaria vaccine (RTS,S) through improved manufacturing efficiencies, expanded production and minimal profit margins ...

Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world’s first malaria vaccine for children ‘RTS,S’ developed by GSK, PATH and partners, by ...

Hyderabad-based Bharat Biotech has partnered with GSK—a British multinational pharmaceutical and biotechnology company—for the ongoing development and potential use of the Shigella vaccine ...

GSK expects to provide between 28- and 33 million doses of flu vaccine to the U.S. market this fall; about 23 million of that will come from the Quebec plant, Smolenaars Hunter said.

GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults aged 18-49 who are at increased risk of contracting the ...